Friday, March 16, 2018 1:39:24 PM
Could be that the increase in shares,
to 100x times the previous number, is the
ramp-up to the RS. Many reasons for skepticism remain.
HOWEVER, the clinical stage of the device
should NOT be undervalued. If what others
have stated on here is true, and the collection
of data at JHU is ongoing-- wow. This is no fidget spinner.
That could mean huge things as the #s of diseases identified increases.
Imo it will be exponential at the point that a certain
minimum number of sicknesses is identified. That's when there
may be actual need for 100 billion shares. We will see.
SD
Recent VNTH News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:30:06 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM